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Background 
All red blood cells bear different blood group 
antigens on the cell surface which are carried 
on different glycoproteins and glycolipids. As 
blood becomes transfused to another person, 
the recipient’s immune system can respond and 
in some individuals, antibodies are produced 
against the antigens of the donor’s blood cells. 
Some blood group antigens occur as high 
frequency antigens, that is, they are found in 
~99% of the population. Thus, transfusion of 
patients with antibodies to a high frequency 
antigen is dependent on one thing: finding 
sufficient compatible blood. When such a 
patient needs to be transfused, it is too late to 
start screening due to the unfavorable odds of 
finding the appropriate antigen-negative blood. 
Screening should be a preemptive measure in 
larger blood banks to avoid these situations. 
Study design and methods 
A multiplex PCR with sequence specific primers 
(SSPs) was designed and optimized to detect 
alleles encoding 6 different high frequency 
antigens. DNA was amplified directly from a 
whole blood lysate using the Extract-N-Amp 
Blood PCR kit. All negative samples were 
confirmed either serologically or by DNA 
sequence analysis. 
Results 
35 donors with various rare phenotypes were 
discovered in a screening process of 1799 
donors from the southern part of Sweden. 
Conclusion 
The multiplex method required considerable 
optimization of both PCR product size and 
stability but in the end a robust method was 
developed that proved economically viable. 
Each donor test is very cost-effective since 
multiplexing permits 6 typings in one reaction at 
a cost well below that of conventional serologic 
tests. The method has potential also to be used 
in more automated analysis such as fragment 
analysis and direct sequencing. 
All red blood cells have functional molecules 
on the cell surface. They act, for example, 
as ion channels, transporters, adhesion 
molecules or simple glycolipid structures. 
Many of these carry polymorphisms which 
are recognized as blood group antigens. 
When blood becomes transfused to another 
person, the recipient’s immune system may 
react by producing antibodies against the 
antigens of the donor’s blood cells. This 
process takes a couple of days to weeks. 
The immune response to blood varies 
between individuals, some receive 100 
blood units without producing antibodies 
while others receive 1 unit and form 
antibodies.[1]  
 
If the immune system has produced an 
antibody against a blood group antigen, it 
will react if this antigen is encountered 
again; potentially resulting in various 
degrees of immediate or delayed 
transfusion reactions, some being so severe 
that if left untreated could seriously harm or 
kill a patient. 
 
The different antigens on a red blood cell 
are divided into one of 33 different blood 
group systems, of which ABO and Rh are 
the most well known. Some antigens in 
blood group systems are polymorphic, 
others are found either as high frequency 
antigens because they are found in ~99 % 
of the population, or as low frequency 
antigens (found in less than 1% of 
individuals). Generally high frequency 
antigens do not cause any harm since the 
recipient is most likely also positive for the 
antigen. But what if a patient lacks one or 
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more of these high frequency antigens and 
requires blood? 
The possibility to transfuse patients with 
antibodies to high frequency antigens is 
dependent on finding compatible antigen-
negative blood. When the need arises for 
such a patient to be transfused, it is too late 
to start screening donors because the 
likelihood of finding compatible blood is less 
than 1 in 100 typed depending on the 
antigen. [2] Consequently, this scenario 
usually has two outcomes unless antigen-
negative donors are known: to cancel the 
pending operation or to delay the 
transfusion in order to obtain appropriate 
compatible blood from other blood banks or 
the WHO Rare Donor Registry, which may 
take several days. As the blood unit is rare, 
it is most commonly stored frozen, mixed 
with glycerol, in liquid nitrogen (-195oC) or in 
a -80oC freezer. When blood arrives, it 
needs to be washed and resuspended, 
which in the end leads to a blood unit with 
less effect compared to a fresh blood unit. 
Seltsam et al. reviewed current practice in 
Germany, Austria and Switzerland and 
concluded that about one third of patients 
with high frequency antibodies received 
unsatisfactory transfusion therapy. [3]  
 
Similar to hemolytic disease of the newborn 
(HDN), antibodies against platelet antigens 
is the most common cause of fetal and 
neonatal alloimmune thrombocytopenia 
(FNAIT). Platelets are usually much harder 
to work with since they have a short 
lifespan, phenotyping is usually employed 
by flow cytometry or monoclonal antibody 
immobilization of platelet antigens (MAIPA), 
which is very time-consuming. Blood 
centers need to have an inventory of 
human-platelet-antigen (HPA)-negative 
platelet concentrates in case of a FNAIT.[4] 
 
Most blood banks do not have a typing 
program to identify donors that lack high 
frequency antigens and other rare antigens. 
There are few commercially available 
antisera thus forcing blood banks to use 
sera from immunized patients, which is 
unstandardised and of limited supply. 
Patients’ sera also tend to deteriorate upon 
storage and large volumes are needed for 
mass typing. As the sera deteriorate, there 
is a risk of mistyping donor RBCs, denoting 
them antigen-negative when they really are 
weakly antigen-positive thus increasing the 
risk of delayed hemolytic transfusion 
reactions. [5] 
 
The aim of this project was to develop an 
effective and low-cost method to identify 
blood donors with rare blood groups. There 
are several high frequency antigens that are 
clinically relevant and for which, screening 
for the antigen-negative phenotypes would 
be an advantage in a large Blood Centre. 
However traditional serological methods are 
restricted as described above. Since the 
molecular basis of most blood group 
antigens is known, it is possible to decide 
the phenotypic expression of 
patients/donors blood group by simple PCR 
methods. However, current methods of DNA 
preparation demand much "hands-on" time 
and several steps; such as lysing cells, 
removing unwanted byproducts and 
precipitating DNA in alcohol. Thus, we set 
out to develop a multiplex-PCR that takes 
as few steps as possible yet giving a cost 
effective and safe result, starting from 
simple whole blood and move directly to 
PCR amplification and gel separation. 
 
The antigens investigated in this project are 
Coa (1:500), Kpb (1:1500), Sc1 (1:269000), 
Yta (1:1000), HPA-1a (1:100) and Vel 
(1:1250). Numbers in parentheses indicate 
the prevalence of the antigen-negative 
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phenotype. These antigens were picked 
based on demand in our institution and are 
connected to the northern European 
population but this method can be used for 
others as the molecular basis of most blood 
group antigens are known. [2, 6, 7]  
 
Blood group genotyping is already a 
common practice in many blood centers and 
larger Transfusion Services, but only used 
in cases where serological typing is 
impossible due to multiple transfusions or 
problematic serology as a low-throughput 
method. [8-10] 
 
As stated by Avent et al., genotyping is 
already competing with serological methods 
and is becoming routinely used. Though the 
more common serological typing of ABO 
and Rh is favored due to its fast pace, the 
typing of high frequency antigens with SSPs 
in a multiplex PCR can produce large 
amounts of data with a minimal input of 
labor. For instance, manually typing six high 
frequency antigens per donor and 110 
donors a day nets a result 660 typings 
done, a feat which can be improved even 
more if the process is automated.[11] 
 
The southern blood banks of Sweden 
normally receive about 200 to 250 
donations each day where 1 rare blood unit 
could be procured every day without 
knowing it. Designing a mid-throughput 
method of genotyping these high frequency 
antigens could potentially solve smaller 
blood banks issues in identifying rare 
antigen-negative blood. 
 
Materials and methods 
 
Samples 
 
Blood samples (O RhD +/-) in anticoagulant 
citrate dextrose (ACD) solution from donors 
in Skåne were collected within two weeks of 
donation. Each sample was controlled so 
that no previous screening was performed. 
10 μl whole blood was transferred to an 
eppendorf tube and frozen for at least 1 
day. DNA preparation was performed with 
Extract-N-Amp PCR kit (Sigma-Aldrich, 
USA) according to the manufacturer’s 
instructions. The whole sample was mixed 
in with 20 μl lysis buffer. After five minutes 
incubation, 180 μl neutralization buffer was 
added and the samples were used the 
same day. Samples could be kept in +4 C 
for at least a week but it was seldom 
necessary. 
 
DNA preparation using a high-salt 
method 
 
DNA from samples needing sequencing as 
confirmation was prepared with a high-salt 
method: 400 µl of whole blood was frozen 
overnight and then washed with a lysis 
buffer until no hemolysis could be seen. 
The leukocyte pellet was digested with 1 mg 
of Proteinase K in 0.5% SDS/2 mM 
Na2EDTA for 1 hour at 55
 oC. 200 µl 6 M 
NaCl was added and mixed vigorously to 
extract the proteins in the samples, then 
centrifuged for 2 minutes at 14680 rpm. The 
eluate containing DNA was precipitated with 
1 ml 95% ethanol, washed with 1 ml 70% 
ethanol and dried for 1 hour at 55 oC. The 
final pellet was dissolved in sterile water, 
the concentration determined using a 
Nanodrop spectrophotometer and then 
diluted to a concentration of 100 ng/µl. 
 
PCR 
 
A PCR primer mixture was made, 
containing all necessary primers (See table 
1) for CO*A, KP*B, SC*01, YT*A, HPA*1a 
and VEL, cresol red and 25 mM MgCl2. Two 
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ul of the sample lysate were pipetted into 8 
ul of the PCR primer mix and 10 ul Extract-
N-Amp PCR Mix. This was amplified by the 
following program. 
 
Initial denaturation at 94oC for 6 minutes; 10 
two-step temperature cycles: 94oC for 10 
seconds followed by 66oC for 45 seconds; 
30 three-step cycles: 94 oC for 20 seconds, 
annealing at 66oC for 30 seconds and 
elongation at 72oC for 45 seconds. The 
thermal cycling program was completed 
with a final elongation at 72oC for 7 minutes. 
 
Analysis  
 
The PCR products were separated by 
electrophoresis on a 3% agarose gel 
containing Sybr® Safe (Life Technologies, 
USA, a less hazardous alternative to 
ethidium bromide), in 0,5% TBE buffer. After 
separation the gel was photographed under 
UV illumination. 
Each batch of PCR master mix was tested 
with control DNA samples homozygous for 
each of the antithetical low-frequency alleles 
(see figure 1).  
 
  
Figure 1 shows the PCR reaction controlled with a 
DNA sample homozygous for each of the 
antithetical low-frequency alleles (lanes 1-6), 
followed by a water control (lane 7) and a normal 
donor sample prepared with the Extract-N-Amp 
kit (lane 8). The DNA ladder is shown to the left of 
the marked lanes. 
As the likelihood of finding a negative donor 
for all six antigens is less than 1 in a trillion 
(1:2.52·1019), no negative control is needed. 
A water control was included in each PCR. 
If a specific band was absent from a donor 
sample, complementary serological 
investigation or sequencing was done. 
 
Sequence analysis 
 
The only allele needing confirmation by 
sequencing was HPA*1a which was done 
with a general PCR amplification (see table 
1 for sequencing primers) from salt prepped 
DNA and elution with Qiagen Gel Extraction 
Kit following the standard protocol. The 
product was amplified with BigDye® 
Sequencing Mix v3.1, then precipitated with 
60 μl 95% ethanol and 5 μl 125 mM EDTA. 
The precipitate was washed with 250 μl 
70% ethanol and dried in a DNA SpeedVac. 
Band sequencing was performed on an 
Applied Biosystems Genetic Analyzer 3500 
DX according to the manufacturer’s 
specifications. 
 
Serological confirmation 
 
The commercially available reagents, anti-
Kpb (BioRad, USA) and anti-Coa (Immucor, 
USA) were used for serological 
confirmation. Typing for Coa was done with 
IAT tube method, 1 drop antisera and 1 
drop 3% blood suspension, incubation for 
30 min at 37oC followed by 3 washes in 
PBS and addition of 1 drop antihuman 
globulin. 
As no Kp(b-) samples were found, 
serological typing was never performed. 
The method of choice would be the 
standard IAT gel technique, using cards  
containing anti-IgG/-C3d in which 25 µl anti-
Kpb and 50 µl 0.8% blood suspension 
diluted in low ionic saline solution (LISS). 
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The card would then be incubated for 15 
minutes at 37oC followed by 10 min 
centrifugation.  
 
The other three antigens were confirmed 
with noncommercial anti-Vel, anti-Yta and 
anti-Sc1 from our collection of rare sera 
using the IAT gel technique as described 
above for anti-Kpb. 
 
Results 
 
Of the 1799 donors screened, 35 were 
found to lack a high frequency antigen 
investigated in this project: two Vel-
negative, two Co(a–) and 31 HPA-1a-
negative.  
Originally LU*B was included in the mix 
instead of SC*1 but due to poorly 
reproducible PCR amplification, it was 
replaced with SC*1.  
144 samples were screened with the first 
mix containing LU*B primers, 843 with a mix 
without LU*B and 812 with SC*1 primers. 
We felt that the presence of LU*B  primers 
were inhibiting the other primer pairs and, 
by removing LU*B, the success rate for 
each amplification was increased from 
86.8% (19 failed amplifications of 144 
samples) to 96.8% (53  of 1655 samples). 
 
Not every antigen followed the expected 
frequencies, no Yt(a–) and Kp(b-) samples 
were found in this project when at least 1 
was expected (see table 2). The remaining 
antigens followed the expected frequency.  
One sample lacked the CO*A band but 
gave varying results in the serological 
confirmation. The commercial reagent gave 
a weak positive reaction while two different 
patients’ anti-Coa were non-reactive. 
Sequencing was performed and the sample 
had the signature 134C>T mutation that 
results in a Co(a-) phenotype. A control 
sample has been requested.[2] 
 
Work time and costs 
 
The average time for the work process is 3 
hours and 15 minutes with a hands-on time 
of 1 hour 30 minutes. The actual work 
routine was: Thaw three batches (3 x 36) of 
previously frozen samples, gather 36 new 
samples, check the current phenotype, 
mark tubes and transfer 10 μl blood to an 
eppendorf tube. Freeze the new batch while 
preparing the thawed samples and start the 
thermal cycling process for one batch. 
During the cycling, a large agarose gel was 
cast and a new batch of donors were 
gathered, controlled and frozen. As the PCR 
ends and the samples are put through gel 
electrophoresis (see figure 2), the remaining 
two batches are amplified. Optimization 
showed that it was important to start the 
amplification promptly after the PCR 
reactions were prepared and that it could be 
improved with a multichannel pipette. 
Therefore PCR was performed in batches of 
36 samples.  
 
 
Figure 2 - A typical batch of screening donors with a water control in lane 37. 
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As the second and third batches amplify 
there is ample time to gather and finish the 
third batch. When the last two batches are 
amplified, they are separated by 
electrophoresis and the first completed 
batch’s results are put into the database. A 
more detailed flowchart can be found in the 
supplemental info (see the flow chart in 
Figure 7). 
 
The cost of typing donors just based on 
reagents is 35 Kr (3,99€)  per sample.  For 
more detailed cost analysis, see tables 3 
and 4. 
 
Optimization considerations 
 
Although the process was time-consuming 
in the beginning to find the appropriate 
concentration of each primer, it was well 
worth the optimization. Most notable effects 
when using Extract-N-Amp is the high 
annealing temperature needed for 
amplification of the products. A difference of 
1 degree Celsius was critical to the process. 
 
Gels with different DNA markers were 
tested as well. The DNA dye Sybr® Safe 
was compared with GelRed, but GelRed 
gave too great a signal even in at low 
dilution of either dye or amplicon (see figure 
3). 
  
Figure 3 - GelRed gel with 4 and 5 µl DNA in each 
well. The appearance of "bird wings" is due to the 
rough DNA preparation. 
 
Different agarose concentrations were 
examined as well, too low (2%) or too high 
(4%) agarose gel resulted in a separation 
that took too long or gave poor resolution 
(see figure 4 and 5). 
  
Figure 4 - DNA controls with the primer mix without 
LU*B and SC*1 on a 4% agarose gel dyed with Sybr® 
Safe after 50 minutes of electrophoresis at 160V. 
 
 
Figure 5 - Same content as seen in figure 4 except 
2% agarose gel instead of 4% and 40 minutes of 
electrophoresis at 160V. 
 
This process can be compared with Thermo 
Scientifics Phusion kit which is based on a 
similar idea. Phusions recommendation is to 
add 1 μl whole blood straight to the PCR 
tube and amplify with a denaturation 
temperature of 98oC for 1 second and a 
variation of annealing and extension 
temperatures for about 15 seconds/kb. 
While the amplification program is short 
there is a greater risk of nonspecific primer 
binding due to leftovers from blood. 
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The DNA “extraction” with Extract-N-Amp 
also leaves remnants although much more 
diluted. We also found that donors with 
lipemic plasma were not suitable for DNA 
extraction with this method, the lysing buffer 
seemed not to be able to lyse enough 
resulting in a brownish tinted sample 
instead of a more orange/red sample. 
 
 Discussion 
 
The aim of this project was to design and 
optimize a multiplex screening protocol for 
high frequency antigens to suit the needs of 
our Blood Centre. Other blood typing 
methods that use microarrays, eg. 
Beadchip, have large multiplexing 
capabilities but have longer analysis time. 
Hashmi et al. [12, 13] used a semiautomatic 
protocol for DNA extraction of 96 donors 
which took 4 hours. By that time, at least 36 
donors would be completed using the 
Extract-N-Amp method. While the 
Beadchip detects 24 different antigens, it 
has a price that most smaller blood centers 
cannot afford. Montpetit et al. [14] worked 
on a SNPstream® platform (Cologne Center 
for Genomics, Germany) with a similar 
approach to Hashmi et al. but their analysis 
took three days although the sample 
requirement for DNA preparation was only 
one drop of blood. Denomme and Van 
Oene [15] used the same approach as 
Montpetit et al. but focused on 12 common 
blood group SNPs.  
Extract-N-Amp requires a Thermal Cycler 
and gel electrophoresis equipment, which 
are standard genotyping equipment. An 
array method can process several plates in 
parallel which makes it a suitable method in 
larger blood centers while Extract-N-Amp 
is suitable as a medium throughput method. 
[12-15]  
 
One potential disadvantage of multiplexing 
is that when you are searching for a 
particular phenotype you waste reagents 
typing for the other blood groups. While this 
is no major concern in PCR genotyping due 
to the low cost of primers, a microarray, 
such as those described above, is 
specifically designed and minor 
modifications are not possible. A new 
microchip is then needed resulting in a more 
laborsome work than just making a new mix 
with fewer primers. Karpasitou et al. [16] 
gave a price estimate of less than $3 per 
SNP per sample, not including DNA 
preparation and machine costs. While the 
price of Extract-N-Amp, using the method 
described here, is roughly $5 per sample 
not including machine costs, it is possible to 
minimize costs even further to less than $3 
according to Wagner et al.[17] 
 
Typing for blood group antigens using DNA 
methods also has the disadvantage of only 
being able to report the typical (expected) 
variant of the blood group. Rare or new 
nonsense mutations resulting in an antigen 
negative phenotype will be seen as antigen 
positive in DNA typing methods. [18]  For 
instance, the Co(a-) phenotype could be a 
product of three different missense 
mutations, the most common being the 
134C>T screened for in this project. The 
other two, 133G>A and 140A>G, will result 
in a Co(a+)  phenotype in this method, and 
this is not even including the other 6 
different silencing mutations.[2] While rare 
null alleles might be mistyped, patient safety 
is never compromised due to the serological 
confirmation.  
 
Small trial runs using the Extract-N-Amp 
DNA in direct sequencing were also 
performed instead of using high salt-
prepared DNA. While it was possible to 
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obtain decent data, the repeat rate was very 
high, 9 failed runs of 22 instead of the 
normal rate of 10 fails of 57 with salt 
prepared DNA. Lee et al. had more success 
by using AnyDirect and purifying with 
Qiagen Gel Extraction Kit and sequencing 
with BigDye® Terminator Cycle Sequencing 
Kit. This indicates that it is indeed possible 
to sequence individual samples relatively 
quickly.[19] 
 
Fragmentation analysis was also tested on 
the Applied Biosystems Genetic Analyzer 
3500 DX with FAM-labeled primers for 
HPA*1a, YT*A, VEL and CO*A and it gave 
a promising result (see figure 6 in 
supplemental info). Large peaks were seen 
at the different amplicon products but due to 
the rough DNA preparation there was much 
background noise. Diluting the samples 
prior PCR amplification could solve this 
problem.  
 
Of the donors screened, there was no  
Kp(b-) (1:1500) Yt(a-) (1:1000) or Sc:-1 
(1:269 000) donor found. While too few 
donors were screened for Sc1, statistically 
at least one Yt(a-)  and one Kp(b-)  donor 
should have been found in this study, 
however the numbers of donors screened is 
still relatively small. The controls for the mix 
were prepared using the high salt method 
resulting in a much cleaner DNA product but 
a Yt(a-) donor was tested using the Extract-
N-Amp method as well. No discrepancies 
could be seen between the different DNA 
preparation methods. 
 
While optimizing the method, it was hard to 
achieve a negative water control. Weak 
bands could be seen in one water sample 
while the next one was negative. As the 
PCR-ReadyMix is amplifies everything it 
can, sterile handling is an absolute must if 
negative water controls is to be attained. 
The amount of clean DNA needed for 
amplification was as low as 15 ng. 
 
Improvements can be made in this method; 
much of the time is spent on transferring 
material between tubes. In the absence of a 
fully automated robot, a simple multichannel 
pipette could dramatically decrease the time 
spent on sample and PCR preparations. 
 
A similar approach to that of  He et al. [20] 
would be interesting to test as well using the 
Extract-N-Amp method. This group pools 
DNA samples in search of low frequency 
antigens using a multiplex PCR. While the 
pooling might not be necessary due to the 
already favorable price, multiplex PCR 
scanning low frequency antigens with a 
positive control such as human growth 
hormone could benefit blood centers.  
 
In conclusion, we have shown that it is 
possible to develop a multiplex PCR 
capable of phenotyping for six high 
frequency antigens for relatively low cost 
using standard PCR equipment. Based on 
the results of the project, a screening 
program has been implemented in the 
Blood Centre to continue to screen donors 
and to identify blood for immunized patients 
in need of these rare units. 
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Supplemental info 
 
Table 1 – Primer sequences, concentrations and products 
 
Table 2 – General information on the screened blood groups 
 
Antigen Gen Mutation Expected frequency Observed frquency 
Kpb KEL 961C>T 1 0 
HPA-1a GPIIIa 186T>C   18 31 
Yta ACHE 1057C>A 1 0 
Vel SMIM1 Not published 1 2 
Coa AQP1 134C>T 3 2 
Sc1 ERMAP 169G>A 0 0 
 
 
Table 3 – Overview of the work process and time spent 
 
Worksteps Time (Bold = Hands-on Time) 
Gathering samples 6 min 
Marking tubes and protocol, mixing samples 35 min 
DNA Prepping 10 min 
Pipetting in PCR tubes 20 min 
Casting gel (for 120 samples) 8 min 
Pipetting in gel 10 min 
Photographing 1 min 
Thermal Cycling 1 h 45 min 
Total time 1:30/3:15 min 
 
Table 4 – Analytical costs 
 
Consumables Price per analysis 
DNA Stain (Sybr® Safe) 0.275 Kr (0.03€) 
Tubes  1 Kr (0.11€) 
Primers  0.7 Kr (0.08€) 
Extract-N-Amp Blood PCR Kit  23 Kr (2.63€) 
Filter tips  4 Kr (0.46€) 
Agarose  3 Kr (0.34€) 
TBE buffert  3 Kr (0.34€) 
Total 34.975 Kr (3.99€) 
Antigen Forward Primer Reverse Primer 
Concentration 
per primer 
Product 
(bp) 
KP*B CTCTTCCTTGTCAATCTCCATCACTTTAC CGAACCTCTGCTTTAGCAGCATC 0,35 pmol/L 493 
HPA*1a ACTTACAGGCCCTGCCTCT TTCTCTTGCCCACACCTCCCCC 0,25 pmol/L 352 
YT*A GAGCGGTGCCTCCAATGGAC CCACTAGTTACCTGCAGGTTGTG 0,25 pmol/L 303 
VEL CGGAGTCAGCCTAGGGGC CTGGGCGCTCTGCTGGAG 0,2 pmol/L 266 
CO*A TGCCAGCATGGCCAGCGAG ACATCTTCACGTTGTCCTGGAACG 0,3 pmol/L 164 
SC*01 CTCCCAGTTGGCCTTGTCTC TCACCTCCTTGGGTACCGTACC 0,35 pmol/L 138 
HPA*Seq GGCCTGCAGGAGGTAGAGAGTCGC TTCTCTTGCCCACACCTCCCCC 0,3 pmol/L 415 
CO*Seq GTGACAGCCGGGTTGAGGTG TGCCAGCATGGCCAGCGAG 0,3 pmol/L 246 
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Figure 6 - The peak diagram from an Extract-N-Amp sample. The primers would give products of 164 bp 
(CO*A)  266 bp (VEL) 303 bp (YT*A) and 352 bp (HPA*1a). The slight miss in the resulting peaks could be due 
to “stutter” peaks, in which different amplicons of the expected product can differ by two or four base pairs. 
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Figure 7: Flow Chart showing the workflow of sample preparation, amplification and analysis 
 
 
 
